IP Library Granted Patent US 11,046,650
Granted Patent B2
US 11,046,650 · App. 16/720,645 · Granted Jun 29, 2021

Deuterated compounds and uses thereof

Inventors: Todd Brady (Lexington, MA); Scott Young (E. Falmouth, MA); William A. Kinney (Newtown, PA); Susan Macdonald (Danvers, MA)
Assignee: Aldeyra Therapeutics, Inc.
C07D215/38A61K31/47A61K45/06A61P17/00A61P27/02A61P39/00C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,046,650
App. No.
16/720,645
Granted
Jun 29, 2021
Kind
B2
Abstract

The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

Claims (112)

1. A compound of Formula II-A or II-B:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is selected from —NH 2 , —NHD, or —ND 2 ;

R 2 is selected from hydrogen or deuterium;

R 3 is —CD 3 ;

R 4 is —CD 3 ; and

R 5 , R 6 , R 7 , and R 8 are each independently selected from hydrogen or deuterium.

2. The compound of claim 1 , wherein at least one of R 2 , R 5 , R 6 , R 7 , or R 8 is deuterium.

3. The compound of claim 1 , wherein the compound is of Formula II-A, or a pharmaceutically acceptable salt thereof.

4. The compound of claim 3 , wherein at least one of R 2 , R 5 , R 6 , R 7 , or R 8 is deuterium.

5. The compound of claim 1 , wherein each of R 5 , R 6 , R 7 , and R 8 is as defined in an entry set forth in the table below:

Entry

R 5

R 6

R 7

R 8

i

H

H

H

H

ii

H

H

H

D

iii

H

H

D

H

iv

H

D

H

H

v

D

H

H

H

vi

H

H

D

D

vii

H

D

H

D

viii

D

H

H

D

ix

H

D

D

H

x

D

H

D

H

xi

D

D

H

H

xii

H

D

D

D

xiii

D

H

D

D

xiv

D

D

H

D

xv

D

D

D

H

xvi

D

D

D

D

or a pharmaceutically acceptable salt thereof.

6. A compound of the following structure:

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, carrier, or vehicle.

8. A pharmaceutical composition comprising the compound of claim 6 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, carrier, or vehicle.

9. A composition comprising a compound of claim 1 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of about 50% or greater.

10. A composition comprising a compound of claim 1 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of about 80% or greater.

11. A composition comprising a compound of claim 1 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of 90% or greater.

12. A composition comprising a compound of claim 3 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of about 50% or greater.

13. A composition comprising a compound of claim 3 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of about 80% or greater.

14. A composition comprising a compound of claim 3 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of 90% or greater.

15. A composition comprising a compound of claim 5 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of about 80% or greater.

16. A composition comprising a compound of claim 5 , wherein each position of deuterium enrichment in the compound comprises deuterium in an amount of 90% or greater.

17. A composition comprising a compound of claim 6 , wherein each position of deuterium enrichment in R 3 and R 4 comprises deuterium in an amount of about 50% or greater.

18. A composition comprising a compound of claim 6 , wherein each position of deuterium enrichment in R 3 and R 4 comprises deuterium in an amount of about 90% or greater.

19. A composition comprising a compound of claim 6 , wherein each position of deuterium enrichment in R 3 and R 4 comprises deuterium in an amount of 95% or greater.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2020
From: BRADY, TODD; YOUNG, SCOTT; KINNEY, WILLIAM A.; MACDONALD, SUSAN
To: ALDEYRA THERAPEUTICS, INC.
Reel/Frame 051842/0930 →
Continuity (3)
Continuation 15754065
Provisional Application 62208223 · Aug 21, 2015
Related Publication 20200199075A1 · Jun 25, 2020
Cited By (1)
US 12,240,816